These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 22038541)
1. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Matok I; Levy A; Wiznitzer A; Uziel E; Koren G; Gorodischer R Dig Dis Sci; 2012 Mar; 57(3):699-705. PubMed ID: 22038541 [TBL] [Abstract][Full Text] [Related]
2. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy. Daniel S; Matok I; Gorodischer R; Koren G; Uziel E; Wiznitzer A; Levy A J Rheumatol; 2012 Nov; 39(11):2163-9. PubMed ID: 22984274 [TBL] [Abstract][Full Text] [Related]
3. The safety of H(2)-blockers use during pregnancy. Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Uziel E; Levy A J Clin Pharmacol; 2010 Jan; 50(1):81-7. PubMed ID: 19789371 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183 [TBL] [Abstract][Full Text] [Related]
6. The safety of metoclopramide use in the first trimester of pregnancy. Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Levy A N Engl J Med; 2009 Jun; 360(24):2528-35. PubMed ID: 19516033 [TBL] [Abstract][Full Text] [Related]
7. Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations. Goldberg O; Koren G; Landau D; Lunenfeld E; Matok I; Levy A J Clin Pharmacol; 2013 Sep; 53(9):991-5. PubMed ID: 23873250 [TBL] [Abstract][Full Text] [Related]
8. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists. Levy A; Matok I; Gorodischer R; Sherf M; Wiznitzer A; Uziel E; Koren G J Clin Pharmacol; 2012 Jan; 52(1):78-83. PubMed ID: 21343345 [TBL] [Abstract][Full Text] [Related]
9. Risk of major congenital malformations following first-trimester exposure to vaginal azoles used for treating vulvovaginal candidiasis: a population-based retrospective cohort study. Rotem R; Fishman B; Daniel S; Koren G; Lunenfeld E; Levy A BJOG; 2018 Nov; 125(12):1550-1556. PubMed ID: 29790255 [TBL] [Abstract][Full Text] [Related]
10. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations. Matok I; Gorodischer R; Koren G; Landau D; Wiznitzer A; Levy A Br J Clin Pharmacol; 2009 Dec; 68(6):956-62. PubMed ID: 20002091 [TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Nikfar S; Abdollahi M; Moretti ME; Magee LA; Koren G Dig Dis Sci; 2002 Jul; 47(7):1526-9. PubMed ID: 12141812 [TBL] [Abstract][Full Text] [Related]
12. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Gill SK; O'Brien L; Einarson TR; Koren G Am J Gastroenterol; 2009 Jun; 104(6):1541-5; quiz 1540, 1546. PubMed ID: 19491869 [TBL] [Abstract][Full Text] [Related]
13. Teratogenic determinants of first-trimester exposure to antiepileptic medications. Brosh K; Matok I; Sheiner E; Koren G; Wiznitzer A; Gorodischer R; Levy A J Popul Ther Clin Pharmacol; 2011; 18():e89-98. PubMed ID: 21467600 [TBL] [Abstract][Full Text] [Related]
14. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. Choi A; Noh Y; Jeong HE; Choi EY; Man KKC; Han JY; Kim HS; Yon DK; Shin JY JAMA Netw Open; 2023 Jan; 6(1):e2250366. PubMed ID: 36626173 [TBL] [Abstract][Full Text] [Related]
15. The safety of amoxicillin and clavulanic acid use during the first trimester of pregnancy. Daniel S; Doron M; Fishman B; Koren G; Lunenfeld E; Levy A Br J Clin Pharmacol; 2019 Dec; 85(12):2856-2863. PubMed ID: 31486528 [TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. Graner S; Svensson T; Beau AB; Damase-Michel C; Engeland A; Furu K; Hviid A; Håberg SE; Mølgaard-Nielsen D; Pasternak B; Kieler H BMJ; 2017 Feb; 356():j629. PubMed ID: 28246106 [No Abstract] [Full Text] [Related]
17. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Diav-Citrin O; Arnon J; Shechtman S; Schaefer C; van Tonningen MR; Clementi M; De Santis M; Robert-Gnansia E; Valti E; Malm H; Ornoy A Aliment Pharmacol Ther; 2005 Feb; 21(3):269-75. PubMed ID: 15691301 [TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome following opioid exposure: A cohort study. Fishman B; Daniel S; Koren G; Lunenfeld E; Levy A PLoS One; 2019; 14(7):e0219061. PubMed ID: 31260464 [TBL] [Abstract][Full Text] [Related]
19. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Caro JJ; Salas M; Ward A Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776 [TBL] [Abstract][Full Text] [Related]
20. Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy. Källén BA Eur J Obstet Gynecol Reprod Biol; 2001 May; 96(1):63-8. PubMed ID: 11311763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]